Day Lucy 4

4 · AN2 Therapeutics, Inc. · Filed Feb 23, 2026

AI-generated summary of this filing

Updated Feb 23, 2026

AN2 Therapeutics (ANTX) CFO Lucy Day Receives RSU Award (38,000)

What Happened

Lucy Day, Chief Financial Officer of AN2 Therapeutics (ANTX), was granted 38,000 restricted stock units (RSUs) effective Feb 20, 2026 (acquired at $0.00). The same report also shows a derivative disposition of 77,000 shares (reported at $0.00). These entries are reported as awards/grants and a derivative transaction rather than an open-market buy or sale.

Key Details

Transaction date(s): Feb 20, 2026; Form 4 filed Feb 23, 2026 (timely filing).
Grant: 38,000 RSUs acquired, price reported $0.00.
Derivative disposition: 77,000 units reported as disposed, price reported $0.00 (filing does not state reason for disposition).
Shares owned after transaction: not specified in the excerpt of the filing provided.
Notable footnotes:
- F1: The 38,000 RSUs vest 25% annually over four years starting Jan 1, 2026, subject to continued service.
- F2: Includes earlier RSU balances: 27,500 RSUs (vest starting Jan 1, 2024) and 46,500 RSUs (vest starting Jan 1, 2025), each vesting 1/4 annually subject to service.
- F3: Adjusted total includes 5,000 shares purchased under the 2022 ESPP on Mar 31, 2025.
- F4: Option grants (if any) vest monthly (1/48th) over four years from Jan 1, 2026.
No 10b5-1 plan, tax-withholding sale, or late-filing flag is indicated in the provided details.

Context

This filing primarily records compensation-related awards (RSUs). Grants are common executive compensation and do not represent an open-market purchase (a stronger bullish signal) or a sale.
The 77,000-share "derivative disposition" is reported at $0.00; the form excerpt does not explain whether that reflects conversion, cancellation, exercise settlement, or another administrative action.

Form 4

Period: 2026-02-20

Chief Financial Officer

Transactions

Award
Common Stock
[F1][F2][F3]
2026-02-20+38,000→ 118,363 total
Award
Stock Option (right to buy)
[F4]
2026-02-20−77,000→ 77,000 total
Exercise: $1.04Exp: 2036-02-19→ Common Stock (77,000 underlying)

Footnotes (4)

[F1]Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.
[F2]Includes a balance of (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 46,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service through each applicable vesting date.
[F3]Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's 2022 Employee Stock Purchase Plan on March 31, 2025.
[F4]The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2026, subject to the Reporting Person's continuous service through each applicable vesting date.

Signature

/s/ Lucy Day|2026-02-23

1 file